Mani Foroohar
Stock Analyst at Leerink Partners
(1.48)
# 3,281
Out of 4,749 analysts
181
Total ratings
41.18%
Success rate
-12.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $5.60 | +382.14% | 9 | Jan 13, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $46 → $44 | $10.74 | +309.68% | 10 | Nov 19, 2024 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $20 → $19 | $5.43 | +249.91% | 2 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $15.85 | +354.26% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $4.81 | +253.43% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $48.88 | +0.25% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $34.21 | +34.46% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $11.57 | +90.15% | 6 | Oct 16, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $9 → $8 | $7.24 | +10.50% | 7 | Sep 3, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $31.90 | +94.36% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $11.49 | +13.14% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $25.08 | +15.65% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $113.72 | +102.25% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $3.79 | +5.54% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.07 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $6.70 | +362.69% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $23 | $9.42 | +144.16% | 10 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.06 | +560.38% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $19.88 | +101.21% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $39.42 | +135.92% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $10.32 | +713.95% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $1.31 | +434.35% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $180 → $160 | $7.75 | +1,964.52% | 10 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $25.92 | +197.07% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $271.31 | -47.29% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.54 | +8.30% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $41.59 | +82.74% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.43 | +2,277.62% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $4.22 | +373.93% | 6 | Jul 23, 2021 |
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $5.60
Upside: +382.14%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Outperform
Price Target: $46 → $44
Current: $10.74
Upside: +309.68%
Lexeo Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $20 → $19
Current: $5.43
Upside: +249.91%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $15.85
Upside: +354.26%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $4.81
Upside: +253.43%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $48.88
Upside: +0.25%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $34.21
Upside: +34.46%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $11.57
Upside: +90.15%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Market Perform
Price Target: $9 → $8
Current: $7.24
Upside: +10.50%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $31.90
Upside: +94.36%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $11.49
Upside: +13.14%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $25.08
Upside: +15.65%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $113.72
Upside: +102.25%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $3.79
Upside: +5.54%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $8.07
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $6.70
Upside: +362.69%
Dec 22, 2023
Downgrades: Market Perform
Price Target: $23
Current: $9.42
Upside: +144.16%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $1.06
Upside: +560.38%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $19.88
Upside: +101.21%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $39.42
Upside: +135.92%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $10.32
Upside: +713.95%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $1.31
Upside: +434.35%
Jan 23, 2023
Maintains: Market Perform
Price Target: $180 → $160
Current: $7.75
Upside: +1,964.52%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $25.92
Upside: +197.07%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $271.31
Upside: -47.29%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.54
Upside: +8.30%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $41.59
Upside: +82.74%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.43
Upside: +2,277.62%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $4.22
Upside: +373.93%